Search Results for “EC” – Page 167 – media

AstraZeneca’s Tagrisso Gets Breakthrough Therapy Designation

AstraZeneca announced that the FDA has granted Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the first-line treatment of patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
- Source: finance.yahoo
- 576
- October 10, 2017
Company Insight EGFR FDA New Approvals NSCLC
Cardiologs raises $6m in Series A to support ECG Analysis Platform

Cardiologs Technologies said this week it raised $6.4 million in a Series A round of financing to support accelerated commercialization of its Cardiologs ECG Analysis Platform in the US and Europe.
- Source: Massdevice
- 464
- October 10, 2017
Cardiologs Market Views Series
Top 15 Companies

Medtronic top medtech R&D spender in 2022; Abbott to knock Johnson & Johnson off second place spot.
- Source: evaluategroup
- 1,208
- October 7, 2017
Market Reports R&D
Worldwide Medtech vs. Prescription Drug Sales (2009-2022)

Worldwide prescription drug market only forecast to grow at a marginally faster rate than the medtech market. Evaluate consensus forecasts find that the worldwide market for prescription drugs is set to narrowly outperform the medical device market with a 5.2% market growth per year between 2016 and 2022, versus a 5.1% growth rate per year for medical devices.
- Source: evaluategroup
- 1,191
- October 6, 2017
Market Reports prescription
FDA rejects Intarcia’s hotly promoted diabetes drug/device, citing manufacturing issues

Boston-based Intarcia Therapeutics became the latest casualty of the FDA’s manufacturing standards. The agency has rejected Intarcia’s implanted diabetes drug/device, which company execs have long insisted is on a straight path to blockbuster sales.
- Source: Endpts
- 422
- September 29, 2017
Company Insight diabetes implanted
Two Scientists Nab Another $20 Million for Their CRISPR Biotech Eligo Bioscience

Eligo Bioscience, the French microbiome company developing drugs to prevent and treat bacteria-associated diseases, has secured a $20 million Series A round of financing from Khosla Ventures and Seventure Partners, including a $2 million award from the Worldwide Innovation Challenge. This comes just months after Eligo was selected as one of the 30 Most Innovative Companies in 2017 by the World Economic Forum. This funding will enable Eligo to strengthen its biotherapeutic platform, begin clinical trials for its lead indication and extensively grow its international team of scientists, engineers, and executives.
- Source: Biospace
- 520
- September 29, 2017
Market Views microbiome Series
EU green light for Roche’s Tecentriq

Roche has received European Commission(EC) approval for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab) to treat specific lung and bladder cancers. The green light means that it can be used as monotherapy for people in the EU with previously-treated locally advanced or metastatic non-small cell cancer (NSCLC), or those with metastatic urothelial carcinoma (mUC) who have received a platinum-based chemotherapy or who are ineligible to receive cisplatin chemotherapy.
- Source: Pharmatimes
- 559
- September 26, 2017
bladder cancer Company Insight immunotherapy lung
MIT’s new injection tech delivers multiple vaccines with one poke

Regardless of what it’s protecting you against, few people would likely say that getting a vaccine injection is an altogether enjoyable vaccine. Fortunately, engineers at the Massachusetts Institute of Technology are coming to the rescue with a new 3D fabrication technique that could allow for multiple doses of a drug or vaccine to be delivered to a patient over an extended period of time — with just one jab needed.
- Source: digitaltrends
- 720
- September 25, 2017
Company Insight fabrication needle-phobic vaccine
FDA Approves Symbiomix Therapeutics’ Solosec™ (secnidazole) Oral Granules for the Treatment of Bacterial Vaginosis in Adult Women

Symbiomix Therapeutics announced the U.S. Food and Drug Administration (FDA) has approved its lead product Solosec™ (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women.
- Source: news.pharmacodia
- 422
- September 22, 2017
bacterial vaginosis FDA New Approvals
Medtronic secures FDA approval for Intellis spinal cord stimulator

Medtronic has secured the US Food and Drug Administration (FDA) approval for its next generation spinal cord stimulator branded as Intellis platform for the management of certain forms of chronic intractable pain.
- Source: medicaldevices-business-review
- 999
- September 21, 2017
chronic Company Insight spinal cord stimulator

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.